AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

MIGNONE ROBERTO sold $14.4M of TEVA (indirect holdings)

MIGNONE ROBERTO sold 367,600 indirectly-held shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $39.06 ($14.36M total) on 2026-09-18.

Original reporting
SEC EDGAR · MIGNONE ROBERTO
Published Sep 22, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Bearish
high confidence
Mentioned
$TEVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVABearishMed
01

Why it matters

The large sale may trigger short interest and affect TEVA's share price in the short term.

02

Market read

Direct insider sale of $14M is material news for TEVA traders.

03

What to watch

Potential upcoming corporate actions or debt restructuring that prompted the sale.

Relevance 7/10Novelty 8/10Timing: filing disclosed today

Background

SEC Form 4 filing reports insider transactions. Director sales are monitored for market sentiment.

Company-level read

Ticker impact

$TEVABearishHigh confidence
Context

Director Roberto Mignone sold 367,600 shares for $14.36M, reducing his stake to zero.

Expected impact

Potential short-term price decline as market absorbs large insider sale.

Evidence & confidence

A $14M sale by a director is material and likely to be interpreted as a lack of confidence, prompting traders to consider selling or shorting.

Market effects

Sector

May weigh on pharmaceutical sector as insider activity draws attention to TEVA.

Regional

Limited to markets where TEVA trades (US, Europe).

Global

Low global impact beyond TEVA investors.

Counterpoint

What could challenge this read

Insider sale could be unrelated to fundamentals; price may remain stable if earnings are strong.

Key entities

  • Director
    Roberto Mignone

    Director of TEVA who sold his entire stake.

  • Company
    TEVA Pharmaceutical Industries Ltd

    Global pharmaceutical company listed on NYSE (TEVA).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com